Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | TGM2 | P21980 | 6/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739025 | 0.92 | CES1 (0.86) | CES1BCHETGM2PDE3BPDE3A | |
| SCHEMBL30107213 | 0.92 | CES1 (0.86) | CES1BCHETGM2PDE3BPDE3A | |
| SCHEMBL4737998 | 0.84 | CES1 (0.71) | CES1BCHETGM2PDE3BPDE3A | |
| SCHEMBL2267095 | 0.84 | CES1 (0.71) | CES1BCHETGM2PDE3BPDE3A | |
| SCHEMBL11024504 | 0.80 | BCHE (0.67) | CES1BCHEALDH1A1CA1CA2 | |
| SCHEMBL11024507 | 0.80 | BCHE (0.67) | CES1BCHEALDH1A1CA1CA2 | |
| SCHEMBL11890546 | 0.80 | BCHE (0.67) | CES1BCHEALDH1A1CA1CA2 | |
| SCHEMBL7823471 | 0.78 | CES1 (0.64) | CES1BCHETGM2ALDH1A1ALDH2 | |
| SCHEMBL5528413 | 0.77 | CES1 (0.62) | CES1BCHETGM2PDE3BPDE3A | |
| SCHEMBL18256571 | 0.77 | CES1 (0.71) | CES1BCHETGM2ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574426-A | Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer | 湘潭大学 | 2020-08-25 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-113912609-B | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | 江苏大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20070276025-A1 | Indirubin-Type Compounds, Compositions, and Methods for Their Use | MEIJER LAURENT | 2007-11-29 | — | — | US | disclosed |
| EP-1686988-A1 | INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE | THE ROCKEFELLER UNIVERSITY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005041954-A1 | INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE | THE ROCKEFELLER UNIVERSITY (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-0637300-B1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMA (US) | 2001-09-05 | — | — | EP | disclosed |
| US-5885996-A | AN ENZYME INHIBITORS OF THYMIDYLATE SYNTHASE WORKS AS BACTERICIDES, FUNGICIDES INHIBITING YEASTS, FUNGI | AGOURON PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5707992-A | MICROBIOCIDES, ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-01-13 | — | — | US | disclosed |
| US-5430148-A | Antiproliferative quinazolines | AGOURON PHARMACEUTICALS, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0637300-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1993020055-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276025-A1 | Indirubin-Type Compounds, Compositions, and Methods for Their Use | CDK3, GSK3B, CDK7 | CES1 1902/4885BCHE 271/4885TGM2 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.